HCID 69675210, compound → (R)-2-((S)-2-(6-(9,9-difluoro-7-(2-((S)-7-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-1,4-dioxa-7-azaspiro[4.4]nonan-8-yl)-1H-imidazol-5-yl)-9H-fluoren-2-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)-2-oxo-1-phenylethylcarbamic acid methyl ester

HRID 1751555Notes

Reaction equation

COC(=O)N[C@@H](C(C)C)C(N1[C@H](C2NC(C3C=CC(C4C=CC5C(=CC=C(C6NC([C@@H]7CCCN7[C:48](=[O:61])[C@H:49]([NH:56][C:57]([O:59][CH3:60])=[O:58])[C:50]7[CH:55]=[CH:54][CH:53]=[CH:52][CH:51]=7)=NC=6)C=5)C=4)=CC=3)=CN=2)CC2(OCCO2)C1)=O.Cl.Cl.Cl.[F:69][C:70]1([F:122])[C:82]2[CH:81]=[C:80]([C:83]3[NH:87][C:86]([C@@H:88]4[CH2:96][C:91]5([O:95][CH2:94][CH2:93][O:92]5)[CH2:90][N:89]4[C:97](=[O:107])[C@@H:98]([NH:102][C:103](=[O:106])[O:104][CH3:105])[CH:99]([CH3:101])[CH3:100])=[N:85][CH:84]=3)[CH:79]=[CH:78][C:77]=2[C:76]2[C:71]1=[CH:72][C:73]([C:108]1[CH:109]=[CH:110][C:111]3[N:115]=[C:114]([C@@H:116]4[CH2:120][CH2:119][CH2:118][NH:117]4)[NH:113][C:112]=3[CH:121]=1)=[CH:74][CH:75]=2>>[CH3:60][O:59][C:57](=[O:58])[NH:56][C@H:49]([C:50]1[CH:55]=[CH:54][CH:53]=[CH:52][CH:51]=1)[C:48]([N:117]1[CH2:118][CH2:119][CH2:120][C@H:116]1[C:114]1[NH:113][C:112]2[CH:121]=[C:108]([C:73]3[CH:74]=[CH:75][C:76]4[C:77]5[C:82](=[CH:81][C:80]([C:83]6[NH:87][C:86]([C@@H:88]7[CH2:96][C:91]8([O:95][CH2:94][CH2:93][O:92]8)[CH2:90][N:89]7[C:97](=[O:107])[C@@H:98]([NH:102][C:103]([O:104][CH3:105])=[O:106])[CH:99]([CH3:100])[CH3:101])=[N:85][CH:84]=6)=[CH:79][CH:78]=5)[C:70]([F:69])([F:122])[C:71]=4[CH:72]=3)[CH:109]=[CH:110][C:111]=2[N:115]=1)=[O:61]

Participants

Reactant 2

HCID 69675210HCID 69675210, compound

HCID 131733623methyl (S)-1-((S)-8-(5-(9,9-difluoro-7-(2-((S)-pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-ylcarbamate 3 HCl salt

Product 1

HCID 87945791(R)-2-((S)-2-(6-(9,9-difluoro-7-(2-((S)-7-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-1,4-dioxa-7-azaspiro[4.4]nonan-8-yl)-1H-imidazol-5-yl)-9H-fluoren-2-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)-2-oxo-1-phenylethylcarbamic acid methyl ester

Procedure

The title compound was prepared according to the method employed to prepare (S)-1-((S)-8-(5-(4-(6-(2-((S)-1-((R)-2-(methoxycarbonylamino)-2-phenylacetyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)naphthalen-2-yl)phenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-ylcarbamic acid methyl ester, except that methyl (S)-1-((S)-8-(5-(9,9-difluoro-7-(2-((S)-pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-ylcarbamate 3HCl salt was used instead of methyl (S)-3-methyl-1-oxo-1-((S)-8-(5-(4-(6-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)naphthalen-2-yl)phenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)butan-2-ylcarbamate 3HCl salt. MS (ESI) m/z 929.83 [M+H]+. (90 mg, 63%).

Sources & evidence

ORD record: ord-74fa79f6a04249d398937239ef2483a8
Source dataset: uspto-grants-2015_10
DOI: 10.6084/m9.figshare.5104873.v1
Patent number: US09156823B2

Reaction notes

Loading…